Monte Rosa Therapeutics, Inc.
GLUE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001826457
In the last 90 days, Monte Rosa Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 192 institutions reported holding it in 13F filings for Q2 2026, worth $2.24B in total; Duquesne Family Office is the only superinvestor holding it.
Q3 2024 vs. Q2 2024
How the institutions holding Monte Rosa Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 75 | 1 | 81 | +7 |
| Shares | 45.9M | 2.36M | 49.8M | +6.21M (+14.3%) |
| Value | $171.7M | $8.83M | $263.7M | +$100.8M (+61.9%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (14)
Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 2,901,491 | $15.4M | 0.00% |
| Parkwood LLC | 426,620 | $2.26M | 0.28% |
| Ikarian Capital, LLC | 311,593 | $1.65M | 0.51% |
| Marshall Wace, LLP | 173,849 | $921.4K | 0.00% |
| Boothbay Fund Management, LLC | 91,292 | $483.8K | 0.02% |
| HRT Financial LP | 38,911 | $206.0K | 0.00% |
| Bridgeway Capital Management, LLC | 25,000 | $132.5K | 0.00% |
| MetLife Investment Management | 24,855 | $131.7K | 0.00% |
| Sherbrooke Park Advisers LLC | 19,993 | $106.0K | 0.02% |
| Intech Investment Management LLC | 14,457 | $76.6K | 0.00% |
| Two Sigma Investments, LP | 13,500 | $71.5K | 0.00% |
| SG Americas Securities, LLC | 10,419 | $55.0K | 0.00% |
| Sterling Capital Management LLC | 147 | $779 | 0.00% |
| Capital Performance Advisors LLP | 29 | $154 | 0.00% |
Sold out (7)
Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Sarasin & Partners LLP | 65,081 | $243.4K |
| Gsa Capital Partners LLP | 25,346 | $95.0K |
| Squarepoint Ops LLC | 22,665 | $84.8K |
| Castleview Partners, LLC | 18,950 | $70.9K |
| Qube Research & Technologies Ltd | 16,566 | $62.0K |
| Jump Financial, LLC | 16,338 | $61.1K |
| Russell Investments Group, Ltd. | 2,631 | $9.84K |
Not filed for Q3 2024 yet (1)
Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 2,360,093 | $8.83M |